General information
SECRETARIAT AND REGISTRATION DESK
The on-site registration desks will be open during the following days:
- Wednesday, 4 March 2026 07:30 – 20:00
- Thursday, 5 March 2026 07.15 – 19.30
- Friday, 6 March 2026 07.15 – 19.30
- Saturday, 7 March 2026 08:00-13:00
EXHIBITION
An exhibition of pharmaceutical and technical products will take place in the Congress Venue according to the following timetable:
- Thursday, March 5 08:00 – 19:00
- Friday, March 6 08:00 – 19:00
- Saturday, March 7 09:00 – 12:30
ACCESS
All participants will receive instructions for self-registration and printing their badge upon arrival at the venue.
Badges:
- The DELEGATE badge (white) grants access to all scientific sessions, industry symposia and the exhibition area, where catering services are served.
- The FACULTY badge (red) grants access to all scientific sessions, industry symposia and the exhibition area, where catering services are served.
- The SPONSOR badge (blue) grants access to the industry symposia and to the exhibition area.
- The PATIENT badge (green) grants access to the dedicated Patient Catering Area and NPOs area. It doesn’t grant access to industry symposia nor to the exhibition area.
Wearing the badge is mandatory at all times during congress activities. Please note that in case of loss, a reprint fee will be charged for issuing a new badge.
ADMISSION
Participants are kindly requested to wear their badge during all congress activities. The badge will admit to the scientific sessions, exhibition area, coffee breaks and lunches.
OPENING LECTURE
The Opening Lecture, held by the Congress Chairs, Prof. Luís Inês and Prof. Maria José Santos, along with Lupus Europe’s CEO, Jeanette Andersen, will take place on 4 March, at 17:00, in Auditorium I.
OPENING CEREMONY AND WELCOME COCKTAIL
APP
The official Congress App will be soon available on all the stores.
All participants equipped with a tablet or smartphone running iOS or Android will be able to download the app free of charge, gaining access to all real-time updates and congress information.
In addition to browsing the scientific programme and general information, the app will offer the following features:
- Q&A – Join the conversation during sessions by submitting your questions through the session chat
- Venue and Exhibition Area Map – Easily find your way around the venue
- Agenda – Create your own personalised agenda by selecting the sessions you wish to attend. You will receive a notification whenever one of your selected sessions is about to begin.
LANGUAGE
The official language is English. No simultaneous translation will be provided.
CERTIFICATE OF ATTENDANCE
Participants will be able to download and print the certificate of attendance upon completion of the online evaluation form through a dedicated platform. The instructions will be sent by e-mail after the Congress.
ng predictive models for diagnosis, treatment response, and long-term prognosis in SLE and LN.
My background in Medicine, Immunology and Genetics make a unique combination and provide me with the tools I need to successfully carry my projects. For nearly 30 years of my research career I focused in the identification of the genetic basis of SLE as a first building block towards understanding how genes lead to cellular abnormalities that eventually to clinical disease. A main goal of my research is to understand the mechanisms behind disease pathogenesis, identify new biomarkers for prediction of disease outcomes, flares and remission, and find new therapeutic targets, understanding the mechanisms of response and non-response to therapies, and define the heterogeneity of SLE. I am totally committed to the work for lupus, and I believe that only through careful longitudinal analysis of the patients, and proper molecular analyses, will we be able to advance our understanding of this disease. I am using systems biology approaches, -omics data integration and clustering, scRNASeq and other omics methods and bioinformatics approaches in my research. We use also animal models to study their similitudes with the human disease and the understanding of the function of lupus susceptibility genes. By coordinating large multicenter studies in Europe (PRECISESADS – 2014-2019, and 3TR – 2019-2026), I gained important experience in this and in the relationship with the pharmaceutical industry.
In the clinic, I lead the outpatient clinic for SLE patients and systemic connective tissue diseases, providing a renovated approach to their treatment strategies which refers to the latest treat-to-target perspective and optimized drug combination. Besides, I hold continuous multidisciplinary interactions with colleagues from other fields e.g. nephrologists and pulmonologists aimed at harmonizing the approach to our patients and at integrating the latest advancements in rheumatology to deliver the best possible care.